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Abstract
Background—Disability levels for patients with secondary progressive multiple sclerosis
(SPMS) often worsen despite a stable MRI T2 lesion burden. The presence of oxidative stress in
the absence of measurable inflammation could help explain this phenomenon. In this study, the
assessment of an in vivo marker of oxidative stress, cerebral glutathione (GSH), using magnetic
resonance chemical shift imaging (CSI) is described, and GSH levels were compared in patients
with SPMS and healthy controls.
Objective—To assess whether GSH, a key antioxidant in the brain, is lower in the SPMS patients
compared to matched controls.
Methods—Seventeen patients with SPMS (Expanded Disability Status Scale = 4.0–7.0; length of
MS diagnosis = 19.4±7 years) and 17 age- and gender-matched healthy controls were studied.
GSH levels were measured in the fronto-parietal regions of the brain using a specially designed
magnetic resonance spectroscopy technique, CSI of GSH, at 3T.
Results—The levels of GSH were lower for SPMS patients than for controls, the largest
reduction (18.5%) being in the frontal region (p=0.001).
Conclusion—The lower GSH levels in these patients indicate the presence of oxidative stress in
SPMS. This process could be at least partially responsible for ongoing functional decline in
SPMS.
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Multiple sclerosis (MS) has long been characterized as a chronic inflammatory disease of
the central nervous system. While the inflammatory process is well established, recent
studies have emphasized the presence of additional neurodegenerative processes that assume
an increasingly prominent role as the disease advances into its later progressive stage.1
Magnetic resonance imaging (MRI) provides the best index of MS-related inflammatory
processes, marking the early evolution of the disease through the number and size of
gadolinium-enhanced lesions and T1/T2 lesions. 2 However, after a period of time, the
number of enhanced lesions often declines and lesion burden on T2-weighted MRI
stabilizes. 2, 3 Clinically, the occurrence of distinct episodes of MS relapse and remission is
often replaced by a gradual, unremitting worsening of symptoms over time. Some estimate
that as many as 90% of relapsing-remitting patients convert to this secondary progressive
stage of MS (SPMS) over 20 years disease duration. 4 In this later stage, the changes noted
on MRI no longer appear to be inflammatory, but instead are indicative of progressive brain
atrophy stemming from cell loss. Reductions in brain volume become more prominent in
addition to an increase in T1 hypointensities and the development of T2 hypointensities in
deep gray matter structures. 2, 3, 5
Reduction in inflammatory markers in conjunction with progressive worsening of the
disease would suggest that other processes assume greater importance in SPMS. One
possibility is that oxidative stress is a major contributor to neurodegeneration at this stage of
the disease. The importance of oxidative stress in the pathogenesis of MS has been indicated
in several ways. 6-9. For example, lipid peroxidation products are found in plasma from MS
patients. 10 Additionally, the production rates of reactive oxygen intermediates from
inflammatory cells are increased in leukocytes from MS patients 11, 12 and in EAE mice.8
An in vivo biomarker for oxidative stress could be a useful tool, enhancing our
understanding of a possible, post-inflammatory disease process and perhaps serving as a
surrogate marker to monitor disease progression in the later stage of MS.
Glutathione (GSH) is a potent endogenous antioxidant that plays a key role in protecting
cells against oxidative damage by reactive oxygen species such as hydrogen peroxide
generated in the brain. In particular, GSH provides a first line of defense against singlet
oxygen and hydroxyl radicals that are known to cause cellular damage and eventual cell
death by apoptosis or necrosis. 13, 14 Because GSH is consumed in this protective process, a
reduction in GSH levels is observed in brain tissue undergoing oxidative stress. 15 An
expanding body of evidence has shown GSH to be a sensitive indicator of oxidative stress in
various neurodegenerative diseases. 16-19
Non-invasive measurement of GSH levels in patients with MS could offer an important new
parameter for characterizing this disease, monitoring its status and progression, and guiding
improvements in clinical care. Along with a few other groups of investigators, we have
demonstrated the feasibility of GSH detection in the human brain using multiple quantum
filtering techniques of 1H magnetic resonance spectroscopy (MRS). 20-22 We developed the
technique further by incorporating two-dimensional multiple quantum filtered chemical shift
imaging (CSI) of GSH to sample multiple brain regions without additional scan time. 23 In
the present study, we compare quantitative measures of GSH levels in brains of SPMS
patients and healthy controls, thereby evaluating the presence and severity of oxidative
stress in SPMS.
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Seventeen patients with SPMS and 17 healthy controls closely matched to the patients in age
and gender were examined according to the study protocol approved by the Human Subjects
Committee at the University of Kansas Medical Center. MS patients were recruited from the
University of Kansas Multiple Sclerosis Clinic. Patients’ charts were reviewed to ascertain
that each had a definite diagnosis of MS with a previous relapsing history and a gradual
worsening of their function over at least the preceding year. Patients with a history of other
autoimmune diseases, head injury, claustrophobia, or other unstable medical conditions were
excluded. In order to ensure a close matching on age and gender in our samples, we
recruited the controls sequentially to match individual patients. Informed consent was
obtained from all study participants.
MR protocol
All MR scans were performed on a 3 T system (Allegra, Siemens, Erlangen, Germany). A
custom-built quadrature radiofrequency (RF) helmet coil, a partial volume transmit/receive
coil, was used to provide a relatively homogeneous RF field and high sensitivity with
volume coverage above the eyes. 24 After positioning the participant supine in the magnet,
three-plane scout MR images were acquired using a gradient echo sequence to locate the
volume of interest (VOI). The VOI, a 3-cm axial slab for the chemical shift imaging (CSI)
of GSH, was positioned to cover the area above the corpus callosum including the frontal to
parietal regions, and also located in the iso-center of the magnet (Fig. 1A).
Localized automated shimming was performed to optimize static magnetic field
homogeneity in the CSI slice using the Massachusetts General Hospital shimming package.
The shimming routine adjusts all first- and second-order shim currents based on measured
field maps. This shimming provides improved magnetic field homogeneity across the
complete CSI slice, resulting in <7 Hz full width at half maximum (FWHM) of the water
linewidth in the 6×6×3 cm3 volume in the CSI slice.
In vivo mapping of GSH was performed on a CSI slice positioned in the fronto-parietal
regions of the human brain, where localized shimming was applied (Fig. 1). The multiple
quantum filtered CSI sequence for the GSH measurements was based on a two-echo
scheme. 23, 25 The concentrations of GSH were determined using an internal reference
method, which employs the creatine signal acquired simultaneously with those of GSH.
Using creatine as an internal concentration reference provides an automatic correction for
the brain atrophy effect since both GSH and creatine are mostly present in the brain tissue
and concentrations of metabolites in the cerebro-spinal fluid are more than two to three
orders of magnitude lower than those in the brain tissue. 26-28
GSH CSI data were processed with home-written software in IDL 6.3 (RSI, Boulder).
Preprocessing of data includes line broadening of 2 Hz, zero padding of the data to 8192
points. Signals in creatine CSI (Cr CSI) were modeled with two Lorenzian peaks at 3.0 ppm
for creatine and 3.2 ppm for total choline. The spectral line shape of GSH signals at 2.9 ppm
was approximated with two Lorenzian peaks separated by 4 Hz. Co-edited signals from
NAA appeared at around 2.6–2.8 ppm and were approximated by three Lorenzian peaks.
Spectral fitting was performed using Levenberg-Marquardt least-squares minimization
algorithm implemented in the MPFIT curve fitting package (Craig Markwardt). Following
the Cr CSI data fitting, GSH CSI data were fitted using the frequency and phase information
obtained from the corresponding creatine fitting. The GSH concentration was calculated
from the peak area ratio of GSH to creatine in each CSI voxel with a calibration coefficient
determined from measurements of a solution phantom containing GSH and creatine with
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known concentrations, and the creatine concentration from the literature in a similar manner
as we have described previously. 25 The calibration coefficient used in the quantification of
GSH includes the differences between GSH and creatine in longitudinal relaxation, volume
definition and editing efficiency.
GSH concentrations were calculated from the central 5 × 5 cm2 region of the CSI data,
where both the static magnetic field (B0) and the RF field (B1) homogeneity are the most
adjusted for the conservative estimation of GSH. The total area spans portions of both the
frontal and parietal lobe, and the GSH concentration value obtained for this total area is here
labeled as “fronto-parietal.” In addition, it was possible to independently obtain separate
values for the anterior half (2.5 × 5 cm2) and the posterior half (2.5 × 5 cm2) of the total
area. Although the two halves along this horizontal axis do not correspond perfectly with the
frontal and parietal lobes, it is still reasonable to label the anterior concentration value as
“mostly frontal” and the posterior, as “mostly parietal.” Because these values are obtained
from each specified area (mostly frontal, mostly parietal and total) separately and the fronto-
parietal value is not merely the arithmetic average of the two regional values, all three
variables are reported here. Because participants in the MS patient and control groups were
individually matched for age and gender, the concentrations of GSH for the two groups were
compared using paired-sample t tests. Effect sizes were computed between the two groups
using Cohen’s d statistic.
RESULTS
Demographics
Due to the matching procedure, the participants in each group were identical with respect to
age and gender. They ranged from 29 to 62 years of age with a mean ± standard deviation
(SD) of 51 ± 8. Each group consisted of 14 females and 3 males, reflecting the
demographics of MS patients in Kansas City area. Patients’ disability scores on the
Expanded Disability Status Scale (EDSS) 29 ranged from 4.0 to 7.0, with a median of 6.0.
Average age at the time of diagnosis was 31 ± 7 years, and average duration of disease
(since diagnosis) was 19.7 ± 4 years.
Mapping of GSH via multiple quantum filtered chemical shift imaging
GSH CSI was successfully acquired from the fronto-parietal region of the human brain. The
VOI (3 cm thick CSI slab) is indicated by a rectangle in a T1-weighted sagittal image of the
brain of an MS patient (Fig. 1A). Partial views of GSH CSI (Fig. 1B left) and the
corresponding simultaneously measured Cr CSI (Fig. 1B right) are overlaid on anatomical
MPRAGE images from the middle section of the CSI slab. GSH signals of the cysteine β-
CH2 protons at ~3 ppm were clearly detectable in all the CSI voxels. Line shape analysis of
GSH signals revealed that signal contamination from other overlapping resonances around 3
ppm such as creatine, γ-amino butyric acid (GABA), and macro molecules was minimal,
demonstrating a robust detection of GSH signals in the GSH CSI through the doubly-
selective multiple quantum filtering. Consistent line shape and flat baseline shown in Cr CSI
(Fig. 1B right) demonstrate a good spectral quality of the CSI data. The peak height of the
choline signal at 3.2 ppm was lower than those in the conventional CSI due to the use of a
selective refocusing pulse centered at 3.0 ppm providing complete refocusing of the Cr
signal at 3.0 ppm and partial refocusing of the choline signal at 3.2 ppm.
GSH levels in SPMS patients and healthy controls
GSH levels in the total fronto-parietal area and in each sub-region were lower for the MS
patients than for the controls (Fig. 2). In the fronto-parietal area, the concentration of GSH
for the MS patients was 1.04 ± 0.13 μmol/g compared to 1.19 ± 0.15 μmol/g for the
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controls, with a reduction of 12.5% (p = 0.005; Cohen’s d = 1.06). In the mostly frontal
region, the concentration of GSH for the patients was 1.01 ± 0.15 μmol/g (mean ± SD)
compared to 1.23 ± 0.20 μmol/g for the controls, a reduction of 18.5% (p = 0.001; Cohen’s
d = 1.28). In this region, none of the MS patients had GSH levels exceeding the mean value
for the controls. The difference in GSH concentrations was less pronounced in the mostly
parietal region: 1.06 ± 0.13 μmol/g for the patients and 1.14 ± 0.13 μmol/g for the controls,
a reduction of 7.7% (p = 0.05; Cohen’s d = 0.66). In controls, the concentration of GSH was
lower in the parietal region than in the frontal region (p < 0.05, paired t-test), whereas no
significant regional difference in GSH concentration was noted for the MS patients (p =
0.15).
Correlations between GSH levels and demographic or disease-related characteristics
GSH levels did not differ for males and female. There was a non-significant positive
relationship between age and GSH concentration in the overall fronto-parietal area for the
MS patients (r = 0.36); this was due to a significant relationship between age and GSH
concentration in the mostly frontal region for these patients (r = 0.52, N = 17, p = 0.03). The
corresponding correlations for the healthy controls were non-significant.
The fronto-pariental GSH level tended to be lower for patients with higher disability ratings
on the EDSS, but this correlation was not significant (Spearman’s rho = −0.17). The
correlation was attenuated by severe restriction in the variability of the EDSS scores; all but
four of the 17 MS patients having ratings of either 6.0 (n = 10) or 6.5 (n = 3). We did note
that the patient with the highest disability rating (i.e., EDSS = 7.0) also had the second
lowest GSH values.
Disease duration was negatively related to GSH levels in the total fronto-parietal area (r =
−0.25) and in the mostly parietal region (r = −0.26), although neither of these correlations
was significant. Patients’ age at diagnosis was positively related to GSH levels in the fronto-
parietal area (r = 0.55, N = 17, p = 0.02) and in the mostly frontal region (r = 0.55, N = 17, p
= 0.02). Since these GSH concentrations were also positively related to patients’ current age,
we computed partial correlations for age at diagnosis, adjusted for current age. The partial
correlations still indicated a positive relationship between age of onset and GSH levels
(fronto-parietal: partial r = 0.45, df = 14, p = 0.08; mostly frontal: partial r = 0.34, df = 14, p
= 0.20), but were no longer significant.
DISCUSSION
The present in vivo method of GSH measurement affords the opportunity to confirm the
presence and to assess the severity of oxidative stress in MS as well as other diseases. Using
the GSH CSI technique, clear detection of GSH was achieved at a clinical field strength of 3
T. The use of a doubly-selective multiple quantum filtering method enabled us to resolve
GSH signals from other overlapping resonances, which are particularly pronounced at a field
strength of 3 T or lower. Incorporation of the GSH editing technique into the CSI technique
significantly improved the information content, permitting measurement of GSH levels in
the frontal and parietal regions of the brain. Unlike multiple quantum based editing methods,
the possibilities of adapting subtraction-based editing methods to the CSI technique are quite
limited due to the necessity of maintaining effective suppression of overlapping resonances
over extended brain regions as well as their susceptibility to subject movement.
The present study demonstrates that GSH mapping is feasible for clinical scans. The MR
acquisition time for GSH was less than 20 min. This is due to the low concentration of GSH
(around ~1 μmol/g). The advantage of multiple quantum CSI methods is the efficient scan
time for multiple volumes of interest. Conventional CSI of metabolites with high
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concentrations (e.g., NAA at over 8 – 9 μmol/g) requires substantially longer scan times
compared to single voxel 1H NMR spectroscopy; however multiple quantum CSI of
metabolites with low concentrations (e.g., GSH, GABA) requires an almost identical scan
time, while providing biochemical information of multiple regions. It is also true, however,
that the scan-time limitation does necessitate a much larger voxel size for GSH measurement
compared to other prevalent signals such as NAA, creatine and choline.
The simultaneously measured creatine signal serves as a phase and frequency reference for
fitting analysis of the GSH signals, and therefore, the use of this two-echo scheme
significantly improved the reliability of GSH quantification compared to conventional
multiple quantum filtered spectroscopy that lacks any singlet signals. The use of creatine as
an internal concentration reference also provided an automatic correction for the effect of
brain atrophy, which is particularly important in the clinical studies of neurodegeneration
where significant atrophy occurs during the disease progression. Another benefit of the two-
echo scheme is that no additional scan time was required for the Cr CSI as its acquisition
was achieved with no further relaxation delay during each repetition time period. When
using creatine as an internal concentration reference, caution has to be taken as creatine
concentrations could be altered in SPMS. 30-32 In our study, the creatine concentrations
between MS patients and controls were not different in the fronto-parietal regions (p = 0.87,
data not shown). Thus creatine could serve as a concentration reference in this study and the
observed altered GSH levels in MS were not likely due to potential alterations of creatine
levels.
GSH concentrations in this study were within the range of those in the human brain using
biochemical analyses of autopsy specimens. 33, 34 Concentrations in the frontal and parietal
regions of the brains of SPMS patients were clearly lower compared to those of healthy
controls. While the number of subjects in the present study was relatively small (n = 17 per
group), the reduction in GSH found in the patients, particularly in the frontal lobe, was quite
robust. Owing to the close matching between subjects in the two groups, the difference in
GSH concentration cannot be attributed to disparities in age or gender. Instead, this
difference indicates the presence of oxidative stress that could at least partially account for
the continuing decline in function in the absence of inflammatory activity in patients with
SPMS. As previously noted, GSH is an endogenous antioxidant that counterbalances the
generation of reactive oxygen species and thereby prevents oxidative damage to cells. GSH
is consumed in this antioxidant defense 35 and subsequently replenished in the tissues over a
matter of days. 36 Therefore, GSH levels are “dynamic” measures, reflecting the current
status of oxidative stress in the tissue instead of the static markers of accumulated
neurodegeneration (e.g., T1 hypointensities and atrophy) recorded by conventional MRI.
The significant reductions observed in this study indicate a potentially serious ongoing
process of oxidative stress contributing to the neurodegeneration that characterizes SPMS.
Regional mapping of GSH might uncover even greater levels of oxidative stress, perhaps in
specific areas where extensive MS lesions are evident.
Recently, while this work was underway, a significant reduction of GSH was reported for
seven MS patients using a subtraction-based editing method at 7 T. 37 The patients were
found to have significantly lower GSH levels than the controls in gray matter, but not in
white matter. Sample sizes were small, and no information was provided concerning the
comparability of the patients and controls on potentially important factors such as age and
gender or on the severity, duration, and subtype of MS in the patient sample. The reported
finding that differences in GSH levels between MS patients and controls were confined to
gray matter is interesting, but warrants further consideration. The assessment of gray and
white matter differences is possible using the GSH CSI technique, as we have demonstrated
previously in the case of GABA. 38 However, this assessment requires an assumption that
Choi et al. Page 6













the concentrations of the biochemical in question are homogenous throughout the total
region. Our results indicate differences in GSH levels between the mostly frontal and mostly
parietal regions, and therefore separate values for gray and white matter could not be derived
from the present results. In essence, regional heterogeneity precluded efforts to obtain
separate determinations for gray and white matter.
Since this was a small study, the correlations between GSH levels and clinical measures
(EDSS, disease duration, and age of onset) were not conclusive. Further investigation of the
relationships between GSH levels and physical disability measures is warranted. However,
given the dynamic nature of GSH, repeated assessments of disability over time and an
examination of time-lagged correlations with GSH levels would be especially interesting to
pursue. A patient with severe disability but without any notable progression might be
expected to have normal or near normal GSH levels, while a patient with modest but rapidly
worsening disability might have a markedly lower GSH levels. The measurement of GSH
could be particularly useful in identifying patients at high risk for more dramatic disease
progression and therefore warranting more aggressive therapeutic intervention.
The presence of a marked reduction in GSH concentration in the frontal region suggests that
further examination of the relationship between oxidative stress and changes in MS patients’
cognitive impairment may be useful. In particular, the cognitive assessment performed in
such a study should include measures of executive functions known to be associated with
frontal lobe integrity. Future studies also need to address whether reductions in GSH levels
are unique to SPMS or are to be found in other disease subtypes such as relapsing-remitting
and primary progressive MS. The role of oxidative stress early in the course of MS or in
relationship to disease exacerbations is currently undetermined, as is the possible utility of
targeting oxidative stress in a neuroprotective approach aimed at slowing or halting the
progress of this disease. The development of the present CSI technique for measuring GSH
substantially expands opportunities to investigate these issues.
CONCLUSIONS
In this study, the quantitative assessment of GSH in the brains of SPMS patients is
demonstrated using the selective multiple quantum CSI of GSH. Despite the small number
of patients, we demonstrate that GSH levels are markedly reduced in the brains of SPMS
patients compared to healthy controls. Further study is needed to evaluate GSH in patients
with different presentations of MS and to correlate changes in GSH with changes in
functional status in MS patients. Research capitalizing on this approach for evaluating
ongoing oxidative stress could lead to new understanding of the pathogenesis of MS and to
the development of new therapies directed toward the cascade of events associated with
disease progression.
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A) Outline of GSH CSI slice, the VOI, overlaid on a T1-weighted sagittal scout image of the
brain of an MS patient. CSI slice was placed in the fronto-parietal regions with an oblique
orientation based on individual subject head shape and location. The orientation of the CSI
slab was set to have a pitch angle of 14° (axial↔coronal) between the CSI slab and a line
connecting the base of the corpus callosum from genu to splenium in a mid-sagittal slice of
each participant, providing consistent positioning of the VOI. (B) Partial views of the in
vivo oblique GSH CSI (left) and the simultaneously measured Cr CSI (Right) of an SPMS
patient brain. The acquisition parameters were the following: slice thickness=3 cm, matrix
size=8×8, FOV=20 cm, TE/TR=115/1500 ms, spectral width=2 kHz, number of data
point=256, number of averages (NT)=12 and scan time=19 min. Spectra were overlaid on
the corresponding anatomical MR images from the middle of the CSI slice. Line broadening
factors for the spectra were 2 Hz for both GSH CSI and Cr CSI.
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Comparison of GSH levels for SPMS patients (n=17) and controls (n=17). GSH levels were
significantly lower for SPMS patients than for controls in the overall fronto-parietal region
(p=0.005) and the mainly frontal region (p=0.001), whereas GSH levels in mainly parietal
regions are marginally lower for SPMS patients compared to controls (p=0.05). (*) indicates
statistically significance levels of p < 0.05.
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